Beijing Sun Novo Pharmaceutical Research Co Ltd Net Asset Quality Index
Beijing Sun Novo Pharmaceutical Research Co Ltd net asset quality index. Beijing Sun Novo Pharmaceutical Research Co Ltd (688621) has a Net Asset Quality Index of 55.1% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥2.30 Billion minus total liabilities of CN¥1.03 Billion yields net assets of CN¥1.27 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See 688621 book value for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Beijing Sun Novo Pharmaceutical Research Co Ltd (2017–2025)
Net asset quality index of Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025. This chart shows how Beijing Sun Novo Pharmaceutical Research Co Ltd's Net Asset Quality Index has evolved across 9 annual periods from 2017 to 2025. As of March 2026, the index stands at 55.1%, representing net assets of CN¥1.27 Billion against total assets of CN¥2.30 Billion CNY. Check Beijing Sun Novo Pharmaceutical Research tangible equity quality to evaluate the tangible quality of the company's equity base.
Beijing Sun Novo Pharmaceutical Research Co Ltd Net Asset Quality Index by Year (2017–2025)
Beijing Sun Novo Pharmaceutical Research Co Ltd net asset quality index by year from 2017 to 2025. The table below presents the year-by-year Net Asset Quality Index for Beijing Sun Novo Pharmaceutical Research Co Ltd from 2017 to 2025, covering 9 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see market cap of Beijing Sun Novo Pharmaceutical Research.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 54.0% | CN¥1.23 Billion | CN¥2.28 Billion | CN¥1.05 Billion | ▼ -1.5 pp |
| 2024 | 55.5% | CN¥1.10 Billion | CN¥1.99 Billion | CN¥884.65 Million | ▼ -1.3 pp |
| 2023 | 56.7% | CN¥1.06 Billion | CN¥1.86 Billion | CN¥805.76 Million | ▼ -5.3 pp |
| 2022 | 62.1% | CN¥908.23 Million | CN¥1.46 Billion | CN¥554.86 Million | ▲ +0.1 pp |
| 2021 | 61.9% | CN¥769.64 Million | CN¥1.24 Billion | CN¥473.01 Million | ▲ +11.8 pp |
| 2020 | 50.1% | CN¥192.92 Million | CN¥384.86 Million | CN¥191.94 Million | ▲ +8.5 pp |
| 2019 | 41.6% | CN¥118.76 Million | CN¥285.51 Million | CN¥166.76 Million | ▲ +5.0 pp |
| 2018 | 36.6% | CN¥73.82 Million | CN¥201.50 Million | CN¥127.68 Million | ▲ +6.4 pp |
| 2017 | 30.2% | CN¥33.25 Million | CN¥110.07 Million | CN¥76.82 Million | — |